Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia

The treatment of chronic lymphocytic leukemia (CLL) patients with venetoclax-based regimens has demonstrated efficacy and a safety profile, but the emergence of resistant cells and disease progression is a current complication. Therapeutic target of sphingosine kinases (SPHK) 1 and 2 has opened new...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarapura Martinez, Valeria J., Buonincontro, Brenda, Cassarino, Chiara, Bernatowiez, Juliana, Colado, Ana, Cordini, Gregorio, Custidiano, Maria del Rosario, Mahuad, Carolina, Pavlovsky, Miguel A., Bezares, Raimundo F., Favale, Nicolás O., Vermeulen, Mónica, Borge, Mercedes, Giordano, Mirta, Gamberale, Romina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067719/
https://www.ncbi.nlm.nih.gov/pubmed/37020867
http://dx.doi.org/10.3389/fonc.2023.1143881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067719/
https://www.ncbi.nlm.nih.gov/pubmed/37020867
http://dx.doi.org/10.3389/fonc.2023.1143881

Ejemplares similares